Literature DB >> 28387979

Prescription contraception use and adherence by women with substance use disorders.

Gillian Griffith1,2, Tara Kumaraswami3, Stavroula A Chrysanthopoulou4, Kristin M Mattocks4,5, Robin E Clark4,6.   

Abstract

BACKGROUND AND AIMS: Unintended pregnancy rates are high among women with substance use disorders (SUDs), which could be explained partly by lower use of and adherence to contraception. We aimed to test: (1) the association of SUD with prescription contraceptive use, contraceptive method selection and adherence; (2) whether practices participating in the Patient-Centered Medical Home Initiative (PCMHI) had better contraceptive use and adherence for patients with SUD; and (3) for differences in the association of SUD with adherence by type of contraceptive used.
DESIGN: Retrospective cohort analysis of claims and encounter data.
SETTING: Massachusetts, USA. PARTICIPANTS: A total of 47 902 women aged 16-45 years enrolled in Medicaid or Commonwealth Care in Massachusetts between 2010 and 2014. MEASUREMENTS: We examined three dependent variables: (1) use of a reversible prescription contraceptive during 2012; (2) the contraceptive methods used; and (3) the proportion of days covered by a prescription contraceptive in the year following the first prescription contraceptive claim. The primary predictor was diagnosed SUD, defined as at least one claim for an alcohol or drug use disorder.
FINDINGS: SUD was associated with lower rates of prescription contraceptive use during 2012 [19.2 versus 23.9%; adjusted odds ratio (aOR) = 0.79, P < 0.001]. SUD was associated with decreased selection of long-acting reversible contraception (LARC) compared with short-acting contraception (SARC) (42.8 versus 44.5%; aOR = 0.83, P = 0.011). There was no significant association between SUD and adherence (aOR = 0.84, P = 0.068). PCMHI enrollment did not alter the relationship between SUD and contraceptive use or adherence. Contraceptive method did not impact the relationship between SUD and adherence.
CONCLUSION: Women with substance use disorders are less likely to use prescription contraceptives, especially long-acting methods, but are not significantly less likely to adhere to them once prescribed than women without substance use disorders.
© 2017 Society for the Study of Addiction.

Entities:  

Keywords:  Adherence; Medicaid; contraception; long-acting reversible contraception; short-acting reversible contraception; substance use disorder

Mesh:

Year:  2017        PMID: 28387979     DOI: 10.1111/add.13840

Source DB:  PubMed          Journal:  Addiction        ISSN: 0965-2140            Impact factor:   6.526


  5 in total

1.  Contraception and Healthcare Utilization by Reproductive-Age Women Who Use Drugs in Rural Communities: a Cross-Sectional Survey.

Authors:  Ximena A Levander; Canyon A Foot; Sara L Magnusson; Ryan R Cook; Jerel M Ezell; Judith Feinberg; Vivian F Go; Kathryn E Lancaster; Elizabeth Salisbury-Afshar; Gordon S Smith; Ryan P Westergaard; April M Young; Judith I Tsui; P Todd Korthuis
Journal:  J Gen Intern Med       Date:  2022-06-15       Impact factor: 6.473

2.  A Retrospective Chart Review of Contraceptive Use among Adolescents with Opioid Use Disorder.

Authors:  Caitlin J Handy; Hannah L H Lange; Brittny E Manos; Elise D Berlan; Andrea E Bonny
Journal:  J Pediatr Adolesc Gynecol       Date:  2017-11-21       Impact factor: 1.814

3.  Understanding Contraceptive Needs of Women Who Inject Drugs in Orange County: A Qualitative Study.

Authors:  Orli K Florsheim; Dallas Augustine; Megan M Van Ligten; Heike Thiel de Bocanegra; Rachel Perry
Journal:  J Addict Med       Date:  2021 Nov-Dec 01       Impact factor: 3.702

4.  Pregnant or recently pregnant opioid users: contraception decisions, perceptions and preferences.

Authors:  Rebecca L Fischbein; Bethany G Lanese; Lynn Falletta; Kelsey Hamilton; Jennifer A King; Deric R Kenne
Journal:  Contracept Reprod Med       Date:  2018-03-27

Review 5.  Integrating Harm Reduction into Outpatient Opioid Use Disorder Treatment Settings : Harm Reduction in Outpatient Addiction Treatment.

Authors:  Jessica L Taylor; Samantha Johnson; Ricardo Cruz; Jessica R Gray; Davida Schiff; Sarah M Bagley
Journal:  J Gen Intern Med       Date:  2021-06-22       Impact factor: 5.128

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.